Taxanes in combined modality therapy for solid tumors

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

The taxanes, paclitaxel and docetaxel, are novel antimitotic agents that are under extensive investigation in clinical trials. Both taxanes have demonstrated significant activity against many solid tumors as single agents and in combination with other chemotherapeutic agents. In addition, taxanes arrest cells at the G2/M phase of the cell cycle, which is the most radiosensitive phase. These properties are exploited in clinical trials combining this taxane with radiation therapy. Most studies included patients with non-small cell lung cancer (NSCLC) and cancers of the head and neck and there are a few studies with concurrent taxane/RT in esophageal, gastric, pancreatic, brain and breast cancer. Information concerning the tolerability and possible utility of docetaxel is also becoming available. This manuscript will review some of the more prominent trials of the taxanes in combination with radiation therapy for solid tumors.

Original languageEnglish (US)
Pages (from-to)237-247
Number of pages11
JournalCritical Reviews in Oncology/Hematology
Volume37
Issue number3
DOIs
StatePublished - 2001

Fingerprint

Taxoids
Combined Modality Therapy
docetaxel
Neoplasms
Radiotherapy
Clinical Trials
Antimitotic Agents
G2 Phase
Esophageal Neoplasms
Head and Neck Neoplasms
Paclitaxel
Pancreatic Neoplasms
Non-Small Cell Lung Carcinoma
Brain Neoplasms
Cell Division
Stomach Neoplasms
Cell Cycle
Cohort Studies
Breast Neoplasms
taxane

Keywords

  • Non small cell lung cancer
  • RT
  • Taxol

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Taxanes in combined modality therapy for solid tumors. / Choy, Hak.

In: Critical Reviews in Oncology/Hematology, Vol. 37, No. 3, 2001, p. 237-247.

Research output: Contribution to journalArticle

@article{5e71302e495c4777af7de221ddd72ddf,
title = "Taxanes in combined modality therapy for solid tumors",
abstract = "The taxanes, paclitaxel and docetaxel, are novel antimitotic agents that are under extensive investigation in clinical trials. Both taxanes have demonstrated significant activity against many solid tumors as single agents and in combination with other chemotherapeutic agents. In addition, taxanes arrest cells at the G2/M phase of the cell cycle, which is the most radiosensitive phase. These properties are exploited in clinical trials combining this taxane with radiation therapy. Most studies included patients with non-small cell lung cancer (NSCLC) and cancers of the head and neck and there are a few studies with concurrent taxane/RT in esophageal, gastric, pancreatic, brain and breast cancer. Information concerning the tolerability and possible utility of docetaxel is also becoming available. This manuscript will review some of the more prominent trials of the taxanes in combination with radiation therapy for solid tumors.",
keywords = "Non small cell lung cancer, RT, Taxol",
author = "Hak Choy",
year = "2001",
doi = "10.1016/S1040-8428(00)00112-8",
language = "English (US)",
volume = "37",
pages = "237--247",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Taxanes in combined modality therapy for solid tumors

AU - Choy, Hak

PY - 2001

Y1 - 2001

N2 - The taxanes, paclitaxel and docetaxel, are novel antimitotic agents that are under extensive investigation in clinical trials. Both taxanes have demonstrated significant activity against many solid tumors as single agents and in combination with other chemotherapeutic agents. In addition, taxanes arrest cells at the G2/M phase of the cell cycle, which is the most radiosensitive phase. These properties are exploited in clinical trials combining this taxane with radiation therapy. Most studies included patients with non-small cell lung cancer (NSCLC) and cancers of the head and neck and there are a few studies with concurrent taxane/RT in esophageal, gastric, pancreatic, brain and breast cancer. Information concerning the tolerability and possible utility of docetaxel is also becoming available. This manuscript will review some of the more prominent trials of the taxanes in combination with radiation therapy for solid tumors.

AB - The taxanes, paclitaxel and docetaxel, are novel antimitotic agents that are under extensive investigation in clinical trials. Both taxanes have demonstrated significant activity against many solid tumors as single agents and in combination with other chemotherapeutic agents. In addition, taxanes arrest cells at the G2/M phase of the cell cycle, which is the most radiosensitive phase. These properties are exploited in clinical trials combining this taxane with radiation therapy. Most studies included patients with non-small cell lung cancer (NSCLC) and cancers of the head and neck and there are a few studies with concurrent taxane/RT in esophageal, gastric, pancreatic, brain and breast cancer. Information concerning the tolerability and possible utility of docetaxel is also becoming available. This manuscript will review some of the more prominent trials of the taxanes in combination with radiation therapy for solid tumors.

KW - Non small cell lung cancer

KW - RT

KW - Taxol

UR - http://www.scopus.com/inward/record.url?scp=0035111779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035111779&partnerID=8YFLogxK

U2 - 10.1016/S1040-8428(00)00112-8

DO - 10.1016/S1040-8428(00)00112-8

M3 - Article

C2 - 11248579

AN - SCOPUS:0035111779

VL - 37

SP - 237

EP - 247

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 3

ER -